Tags : Myeloma

GSK Reports EMA’s Acceptance of MAA for Belantamab Mafodotin to

Shots: The MAA is based on DREAMM-2 P-II study (DRiving Excellence in Approaches to Multiple Myeloma) study which involves assessing of Belantamab Mafodotin in heavily pre-treated patients with MM who were refractory to an immunomodulatory drug and a proteasome inhibitor and were refractory and/or intolerant to an anti-CD38Ab The study resulted in 31% ORR with […]Read More

Sanofi Report Results of Isatuximab in P-III ICARIA-MM Study for

Shots: The P-III study involves assessing of isatuximab (10mg/kg qw for 4 wks.) + pomalidomide & low dose dexamethasone vs pomalidomide + low dose dexamethasone monothx in 307 patients with r/r MM 96 centers in 24 countries The study resulted in meeting al 1EPs with safe and effective results Isatuximab is used for targeting CD38, […]Read More